Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    TopAbstracts in Hypertension 12/02/2009 - (DGNews)
    Obesity Leading Risk Factor of Left Atrial Enlargement During Aging - (DGNews)
    TopAbstracts in Hypertension 11/25/2009 - (DGNews)
    Team-Based Care Involving a Pharmacist Improves Blood Pressure Control - (DGNews)
    Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study - (BMJ)

    News archive

     Recent webcasts/CME - Hypertension
    • State of the Art in Pulmonary Arterial Hypertension
    • Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment
      Treating Coronary Artery Disease in Vulnerable Adults
      Thrombotic Thrombocytopenic Purpura: The Masquerader

      Webcasts/CME archive

       Recent cases - Hypertension
        A Woman with Swollen Fingers and New-Onset Hypertension and Renal Failure
        Hypertension
        Medical Management of a Pregnancy Woman with Moderate Renal Insufficiency and Superimposed Preclampsia
        Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Losartan Superior to Atenolol For Reducing Cardiac Death From Arrhythmias In Hypertensive Diabetics

        Lancet

        08/21/2003
        By Joene Hendry


        Hypertensive therapy with losartan affords better protection than atenolol against cardiac death from arrhythmias in patients with diabetes mellitus according to data from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

        "Results of our post-hoc analysis showed a close to 50% risk reduction in sudden death in losartan-treated patients with diabetes compared with those treated with atenolol," writes Professor Lars H. Lindholm, MD, of Umea University Hospital, Sweden and colleagues. They studied 586 patients taking once daily losartan versus 609 patients undergoing an atenolol-based antihypertensive therapy. The patients, 53% women, were a mean age of 67 years and diabetic, with left ventricular hypertrophy and an average blood pressure of 177/96 mm Hg.

        After a mean follow up of 4.7 years the researchers report that 44 patients died of sudden cardiac death, 14 (2%) in the losartan group compared with 30 (5%) in the atenolol group.

        Among 191 patients with atrial fibrillation at baseline or during the trial, 10% experienced sudden cardiac death compared with 2% of the 1004 patients without atrial fibrillation. In the losartan group 5 of the 86 patients (6%) with atrial fibrillation at baseline or during the trial experienced sudden cardiac death compared with 9 of the 500 patients (2%) without atrial fibrillation. Among the atenolol group 14 of the 105 patients (13%) with atrial fibrillation compared with 16 of 504 patients (3%) without atrial fibrillation experienced sudden cardiac death.

        In the losartan-treated patients the findings of reduced risk were independent of other risk factors for sudden cardiac death, but the researchers note that their analyses "were exploratory and require confirmation."

        In an associated commentary Wilbert S. Aronow, MD, of Westchester Medical Center and New York Medical College, Valhalla, United States agrees that data from the LIFE trial shows the superiority of losartan over atenolol therapy for hypertensive diabetic patients with left ventricular hypertrophy. He notes however, that a large double-blind randomised trial is needed to determine whether losartan is better, similar, or worse than other beta-blockers including propranolol, timolol, metroprolol, or carvedilol in reducing sudden cardiac death and coronary events among this patient population. Such trials, Dr. Aronow adds, should stratify by risk for complex ventricular arrhythmias, atrial fibrillation, and left- ventricular ejection fraction prior to patient randomisation.
        Lancet 2003;362:619-20.

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send